ASG 15ME

Drug Profile

ASG 15ME

Alternative Names: ASG-15ME

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agensys; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bladder cancer; Urogenital cancer

Most Recent Events

  • 07 Oct 2016 Efficacy and adverse event data from a phase I trial in Urogenital cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 06 Jun 2016 Interim efficacy and adverse event data from a phase I trial in Bladder cancer (Metastatic disease, Second-line therapy or greater) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 21 Apr 2016 Phase-I development is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top